Inzen Tx Patents

Patent portfolio assigned to Inzen Tx (verified via public assignee records). Inzen Therapeutics, a Flagship Pioneering biotech (Cambridge, MA) exploring cell-death/interoception biology. In May 2022 it merged with Yumanity remnants to form Sonata Therapeutics (so no longer standalone). Patents: Inzen Therapeutics Inc. appears as assignor on US20230114107A1 (anti-cancer therapies with inducers of iron-dependent cellular disassembly). Preclinical biotech - no commercial customers; clean 'direct competitor' list not meaningful, Sonata is the successor entity rather than a competitor.